Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions.

[1]  D. DeMets,et al.  Aspirin Increases Nitric Oxide Formation in Chronic Stable Coronary Disease , 2013, Journal of cardiovascular pharmacology and therapeutics.

[2]  C. Hennekens,et al.  Prevention: Aspirin in primary prevention—good news and bad news , 2012, Nature Reviews Cardiology.

[3]  Peter M. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomized trials , 2011 .

[4]  D. DeMets,et al.  Statistical association and causation: contributions of different types of evidence. , 2011, JAMA.

[5]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[6]  D. DeMets,et al.  A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans , 2010, Journal of cardiovascular pharmacology and therapeutics.

[7]  J. Dalen.  Aspirin for the primary prevention of stroke and myocardial infarction: ineffective or wrong dose? , 2010, The American journal of medicine.

[8]  D. DeMets,et al.  The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. , 2009, JAMA.

[9]  G. Jackson,et al.  Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. , 2009, Cardiovascular research.

[10]  C. Hennekens,et al.  The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease , 2008, Expert review of cardiovascular therapy.

[11]  Alessandro Filippi,et al.  Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins , 2007, Trials.

[12]  J. Zweier,et al.  Evidence for the Pathophysiological Role of Endogenous Methylarginines in Regulation of Endothelial NO Production and Vascular Function* , 2007, Journal of Biological Chemistry.

[13]  U. Förstermann,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.

[14]  C. Hennekens,et al.  The role of aspirin in cardiovascular diseases – forgotten benefits? , 2004, Expert opinion on pharmacotherapy.

[15]  H. Schröder,et al.  Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. , 2003, Biochemical and biophysical research communications.

[16]  H. Schröder,et al.  Aspirin Protects Endothelial Cells From Oxidant Damage Via the Nitric Oxide-cGMP Pathway , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[17]  D. Berry,et al.  Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. , 2003, Archives of internal medicine.

[18]  M. Pfeffer,et al.  Use of Statins and Aspirin to Reduce Risks of Cardiovascular Disease , 2002, Journal of cardiovascular pharmacology and therapeutics.

[19]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[20]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[21]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[22]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[23]  J. Buring,et al.  The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States. , 1994, Archives of internal medicine.

[24]  S. Moncada,et al.  Direct electrochemical measurement of nitric oxide released from human platelets. , 1993, Biochemical and biophysical research communications.

[25]  J. Manson,et al.  A prospective study of aspirin use and primary prevention of cardiovascular disease in women. , 1991, JAMA.

[26]  J. Buring,et al.  Epidemiology in Medicine , 1987 .

[27]  H. Jacobs,et al.  Value of bromocriptine in unexplained primary infertility: a double-blind controlled trial. , 1979, British medical journal.

[28]  B Rosner,et al.  A Case-Control Study of Regular Aspirin Use and Coronary Deaths , 1978, Circulation.

[29]  H Jick,et al.  Regular aspirin use and myocardial infarction. , 1976, British medical journal.

[30]  E. C. Hammond,et al.  Aspirin and coronary heart disease: findings of a prospective study. , 1975, British medical journal.

[31]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[32]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[33]  W. H. Wilkinson,et al.  Traumatic Retroperitoneal Rupture of Duodenum , 1954, British medical journal.

[34]  Craven Ll.  Acetylsalicylic acid, possible preventive of coronary thrombosis. , 1950 .

[35]  H. Schröder.  Nitric oxide and aspirin: a new mediator for an old drug. , 2009, American journal of therapeutics.

[36]  C. Hennekens,et al.  Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis , 2006, Nature Clinical Practice Cardiovascular Medicine.

[37]  Nelson.  Asprin in reducing events in the elderly - ASPREE , 2006 .

[38]  J. McNeil,et al.  Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly , 2003, Drugs & aging.